The company depends on raw materials, including specialized items such as viral vectors for therapeutic payloads, some of which are sourced from limited or sole suppliers. It has contracted a third-party contract manufacturing organization (CMO) to produce viral vectors and certain drug products for clinical trials, with expectations that the CMO will meet clinical and potential commercial demands. To support larger clinical trials and commercial manufacturing, the company may need to expand production capacity with existing third parties, secure alternative suppliers, or develop internal manufacturing capabilities. Production risks include equipment malfunctions, contamination, raw material shortages, natural disasters, utility disruptions, human error, and supplier-related issues. Compliance with regulatory requirements by the CMO is essential, as noncompliance could result in delays, sanctions, or other adverse outcomes. While the company believes alternative supply sources are available, it recognizes that establishing new supplier relationships may involve delays or additional costs.
Genenta Science S P A's Comment on Supply Chain
The company depends on raw materials, including specialized items such as viral vectors for therapeutic payloads, some of which are sourced from limited or sole suppliers. It has contracted a third-party contract manufacturing organization (CMO) to produce viral vectors and certain drug products for clinical trials, with expectations that the CMO will meet clinical and potential commercial demands. To support larger clinical trials and commercial manufacturing, the company may need to expand production capacity with existing third parties, secure alternative suppliers, or develop internal manufacturing capabilities. Production risks include equipment malfunctions, contamination, raw material shortages, natural disasters, utility disruptions, human error, and supplier-related issues. Compliance with regulatory requirements by the CMO is essential, as noncompliance could result in delays, sanctions, or other adverse outcomes. While the company believes alternative supply sources are available, it recognizes that establishing new supplier relationships may involve delays or additional costs.
Sources:
Genenta Science S p a 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Genenta Science S p a ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
